Q3 2024 saw continued clinical progress and strategic planning for SpectraCure, but losses widened and liquidity remains a concern as new studies increase funding needs. The company is seeking additional financing to support ongoing development.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.